Endogenous Follistatin-like 1 guarantees the immunomodulatory properties of mesenchymal stem cells during liver fibrotic therapy

BACKGROUND: Mesenchymal stem cell (MSC) therapy has been shown to be a promising option for liver fibrosis treatment. However, critical factors affecting the efficacy of MSC therapy for liver fibrosis remain unknown. Follistatin-like 1 (FSTL1), a TGF-β-induced matricellular protein, is documented as...

Descripción completa

Detalles Bibliográficos
Autores principales: Zheng, Xiaohong, Zhou, Xia, Ma, Gang, Yu, Jiahao, Zhang, Miao, Yang, Chunmei, Hu, Yinan, Ma, Shuoyi, Han, Zheyi, Ning, Wen, Jin, Boquan, Zhou, Xinmin, Wang, Jingbo, Han, Ying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9356430/
https://www.ncbi.nlm.nih.gov/pubmed/35932064
http://dx.doi.org/10.1186/s13287-022-03042-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9356430/
https://www.ncbi.nlm.nih.gov/pubmed/35932064
http://dx.doi.org/10.1186/s13287-022-03042-4

Ejemplares similares